Form 4: Axsome Therapeutics Director Mark Coleman Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Director Mark Coleman of Axsome Therapeutics sold shares of common stock on May 28 and May 29, 2024, under a pre-approved 10b5-1 trading plan.
Summary
- Mark Coleman, a director at Axsome Therapeutics, sold shares of the company's common stock on May 28 and May 29, 2024.
- The sales were executed under a pre-approved 10b5-1 trading plan.
- On May 28, 2024, 5,249 shares were sold at a weighted average price of $75.2095, with prices ranging from $75.00 to $75.88.
- On May 29, 2024, 5,248 shares were sold at a weighted average price of $75.1396, with prices ranging from $75.00 to $75.90.
- Following these transactions, Coleman directly owns 14,600 shares of Axsome Therapeutics.
- The sales represent the disposal of underlying shares of previously exercised stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading arrangement and do not necessarily reflect a change in the director's view of the company's prospects.
Industry Context
Sales by insiders are a common occurrence and are often planned in advance, especially through 10b5-1 plans. The market typically analyzes these sales in the context of the company's overall performance and future prospects.
Comparison to Industry Standards
- Insider sales are a regular part of corporate governance, with executives and directors often holding significant stock options or shares.
- Companies like Pfizer, Johnson & Johnson, and Merck also see regular insider trading activity, often related to pre-planned sales for personal financial management.
- The key is whether the sales are perceived as a lack of confidence in the company's future, which is less likely when sales are conducted under a 10b5-1 plan.
Stakeholder Impact
- The stock sales could have a minor impact on shareholders if perceived negatively, but the 10b5-1 plan mitigates this concern.
- Employees are unlikely to be directly affected by these transactions.
Key Dates
| Date | Description |
|---|---|
| 05/28/2024 | Sale of 5,249 shares of common stock at a weighted average price of $75.2095. |
| 05/29/2024 | Sale of 5,248 shares of common stock at a weighted average price of $75.1396. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.